Investments, Funding & Disinvestment

The acquisition grants Biogen access to two already-marketed medications that generated USD689 million in sales last year.

For MSD, this acquisition is part of a broader strategy to diversify its pipeline before its blockbuster immunotherapy Keytruda loses patent protection.

CVC first invested in Recordati in 2018, paying €3.03 billion (USD 3.5 billion) to acquire a 51.8% controlling stake.

TB remains the deadliest infectious disease in the world, and a single untreated case can infect between 15 and 20 people within a year, making early diagnosis and uninterrupted treatment critical tools for containing any outbreak.

The acquisition signals Novartis’s confidence that Exl-111 can outperform this proven therapy by taking an entirely different approach.

The hospital will roll out in four phases covering technical planning, project management, commissioning, and full operational launch under Apollo’s brand.

The gathering brought together ministers, investors, industry leaders, and development partners to unlock fresh capital for the sector.

Gilead will pay USD1.68 billion upfront and commit up to USD500 million in milestone payments to secure gamgertamig (OM336), Ouro’s BCMA/CD3-targeting TCE.

The 460,000-square-foot factory will sit on a 79-acre plot within the Rowen innovation district, near Dacula, Georgia, approximately 35 miles northeast of downtown Atlanta.